MedTrace Logo

Helminth-induced Immunomodulation Therapy (HINT) in Relapsing-remitting Multiple Sclerosis

NCT00645749 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2019-02-06

No results posted yet for this study

Summary

The hypothesis of this study is that helminth-induced immunomodulation therapy (HINT) will be safe and effective when administered orally in patients with relapsing-remitting multiple sclerosis (RRMS).

Conditions

  • Relapsing Remitting Multiple Sclerosis

Interventions

BIOLOGICAL

Helminth ova

2500 ova per dose (liquid form)

Sponsors & Collaborators

  • National Multiple Sclerosis Society

    collaborator OTHER

  • University of Wisconsin, Madison

    lead OTHER

Principal Investigators

  • John O Fleming, MD · University of Wisconsin, Madison

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-07-31
Primary Completion
2015-08-13
Completion
2015-08-13

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00645749 on ClinicalTrials.gov